FDA Requests Removal of Suicidal Ideation Warning for GLP-1 Medications

U.S. health authorities—the Food and Drug Administration (FDA)—have requested the removal of warnings regarding the risk of suicidal behavior or thoughts associated with the use of GLP-1 receptor agonists. The decision follows a regulatory review that found no increased risk, Bloomberg News reports.

The decision covers medications such as Novo Nordisk’s Wegovy—a GLP-1-based drug developed and approved for obesity treatment—as well as Eli Lilly’s competing product, Zepbound.

According to Bloomberg News, the analysis is based on a large-scale study involving 91 placebo-controlled clinical trials with a total of 107,910 patients. The data showed no increased incidence of suicidal thoughts or behavior among patients treated with GLP-1 medications compared to placebo groups.

The FDA’s findings support the continued use of these drugs in treating obesity and metabolic disorders, confirming their favorable safety profile regarding mental health.